1. People

Ahmad Shariftabrizi, MD

Clinical Assistant Professor of Radiology-Division of Nuclear Medicine

Current Positions

  • Clinical Assistant Professor - Radiology

Education

  • Clinical Fellow in Nuclear Oncology, Division of Nuclear Medicine and Molecular Imaging, Memorial Sloan Kettering Cancer Center, New Nork, NY
  • Clinical Fellow in PET/CT, Division of Nuclear Medicine and Molecular Imaging, University of Pittsburgh Medical Center, Pittsburgh, PA
  • Resident in Nuclear Medicine and Molecular Imaging, State University of New York at Buffalo, NY
  • Postdoctoral Scholar in Molecular Imaging, Rudy L. Ruggles Biomedical Research Institute, University of Vermont, Danbury, CT
  • Postdoctoral Scholar in Translational Medical Research, Massachusetts General Hospital-Bertucci Center for Genitourinary Cancers, Harvard Medical School, MA
  • Postdoctoral Scholar in Investigational Cancer Research, Department of Dermatology, Boston University School of Medicine, MA
  • MD, Tehran University of Medical Sciences, Iran

Selected Publications

  • Saad Aldine A, Balaawi K, Saadeddin A, Shariftabrizi A, Kandemir S. Multifocal Meningiomas mimicking metastasis on 18F-Fluciclovine PET/CT. Nucl Med Mol Imaging. 2021 Oct; 55(5):261-264.
  • Shariftabrizi A, Pillenahalli Maheshwarappa R, Kahn D, Pollard J. 18F-Fluciclovine-Avid Mediastinal Lymph Node Metastasis of Cutaneous Malignant Melanoma. Clin Nucl Med. 2021; 46(2):e97-e99.
  • Shariftabrizi, A. et al (2021). Vascular system. In A. Gholamrezanezhad, M. Assadi, H. Jadvar (Eds). Multidisciplinary Diagnostic Imaging: Radiology-Nuclear Medicine Correlative Imaging. Hoboken, New Jersey: Wiley–Blackwell Publishing.
  • Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, Madjd Z. Common Molecular Markers between Circulating Tumor Cells and Blood Exosomes in Colorectal Cancer: A Systematic and Analytical Review. Cancer Manag Res. 2019; 11:8669-8698.
  • Mansoori M, Roudi R, Abbasi A, Abolhasani M, Isa Abdi Rad I, Shariftabrizi A, Zahra Madjd. High GD2 expression defines breast cancer cells with enhanced invasiveness. Exp Mol Pathol. 2019; 109:25-35.
  • Saeednejad Zanjani L, Madjd Z, Abolhasani M, Rasti A, Shariftabrizi A, Mehrazma M, Fodstad Ø, Asgari M. Human telomerase reverse transcriptase protein expression predicts tumor aggressiveness and survival in patients with clear cell renal cell carcinoma. Pathology. 2019; 51(1):21-31.
  • Korourian A, Madjd Z, Roudi R, Shariftabrizi A, Soleimani M. Induction of miR-31 causes increased sensitivity to 5-FU and decreased migration and cell invasion in gastric adenocarcinoma. Bratisl Lek Listy. 2019; 120(1):35-39.
  • Zanjani LS, Madjd Z, Abolhasani M, Shariftabrizi A, Rasti A, Asgari M. Expression of CD105 cancer stem cell marker in three subtypes of renal cell carcinoma. Cancer Biomark. 2018; 21(4):821-837.
  • Rastegar R, Akbari Javar H, Khoobi M, Dehghan Kelishadi P, Hossein Yousefi G, Doosti M, Hossien Ghahremani M, Shariftabrizi A, Imanparast F, Gholibeglu E, Gholami M. Evaluation of a novel biocompatible magnetic nanomedicine based on beta-cyclodextrin, loaded doxorubicin-curcumin for overcoming chemoresistance in breast cancer. Artif Cells Nanomed Biotechnol. 2018; 24:1-10.
  • Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma. Exp Mol Pathol. 2017; 103(2):218-228.

Our People